ILMN Stock Illumina, Inc.
US · NasdaqGSLast in our picks 2026-10-20 — not in the current list; analysis below is from that screen
Genomics recovery potential and strategic optionality offer turnaround value despite execution risks.
Future value: $310.00 (+18.02%) · 6-12 months
Signal breakdown
- ▸RBC maintained Buy with a $310 target.
- ▸Above 50-day MA (+12.29%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (78.3% of range) — strength
Is ILMN a buy right now?
Trend: ILMN is trading above the 50-day average (+11.42%), RSI 57 — neutral momentum, with a 3-month return of +42.20%.
Valuation & quality: Illumina, Inc. trades on a trailing P/E of 50.6, forward P/E 44.2, PEG 3.32, price-to-book 14.42; fundamentals show net margin 18.3%, return on equity 32.3%, revenue growth 9.4% year on year.
Analyst consensus: 20 analysts have a mean 12-month price target of $248.90 (-8.2% vs the last close; range $113.00 – $365.00), consensus rating “hold”.
Our screen: STRONG BUY (score 4) — Genomics recovery potential and strategic optionality offer turnaround value despite execution risks.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -8.30% | +2.80% | +28.60% | +7.90% | +16.60% | +4.20% | +28.10% | -1.60% |
Fundamentals
Analyst price target
Technical signals
About Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Sector: Healthcare · Industry: Diagnostics & Research · United States · 8,600 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.